UNC Lineberger Comprehensive Cancer Center; Department of Biostatistics, UNC School of Medicine, Chapel Hill, North Carolina, USA.
Clin Cancer Res. 2011 Oct 15;17(20):6542-52. doi: 10.1158/1078-0432.CCR-10-1604. Epub 2011 Sep 9.
We evaluated X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1) protein in head and neck squamous cell carcinoma (HNSCC) patients in association with outcome.
XRCC1 protein expression was assessed by immunohistochemical (IHC) staining of pretreatment tissue samples in 138 consecutive HNSCC patients treated with surgery (n = 31), radiation (15), surgery and radiation (23), surgery and adjuvant chemoradiation (17), primary chemoradiation (51), and palliative measures (1).
Patients with high XRCC1 expression by IHC (n = 77) compared with patients with low XRCC1 expression (n = 60) had poorer median overall survival (OS; 41.0 months vs. OS not reached, P = 0.009) and poorer progression-free survival (28.0 months vs. 73.0 months, P = 0.031). This association was primarily due to patients who received chemoradiation (median OS of high- and low-XRCC1 expression patients, 35.5 months and not reached respectively, HR 3.48; 95% CI: 1.44-8.38; P = 0.006). In patients treated with nonchemoradiation modalities, there was no survival difference by XRCC1 expression. In multivariable analysis, high XRCC1 expression and p16(INK4a)-positive status were independently associated with survival in the overall study population (HR = 2.62; 95% CI: 1.52-4.52; P < 0.001 and HR = 0.21; 95% CI: 0.06-0.71; P = 0.012, respectively) and among chemoradiation patients (HR = 6.02; 95% CI: 2.36-15.37; P < 0.001 and HR = 0.26; 95% CI: 0.08-0.92, respectively; P = 0.037).
In HNSCC, high XRCC1 protein expression is associated with poorer survival, particularly in patients receiving chemoradiation. Future validation of these findings may enable identification of HNSCC expressing patients who benefit from chemoradiation treatment.
我们评估了中国仓鼠细胞 1（XRCC1）蛋白在头颈部鳞状细胞癌（HNSCC）患者中的 X 射线修复缺陷修复（XRCC1）蛋白与预后的关系。
通过对 138 例连续接受手术（n=31）、放疗（15）、手术加放疗（23）、手术加辅助放化疗（17）、单纯放化疗（51）和姑息治疗（1）的 HNSCC 患者的预处理组织标本进行免疫组织化学（IHC）染色，评估 XRCC1 蛋白的表达。
通过 IHC 检测到高 XRCC1 表达的患者（n=77）与低 XRCC1 表达的患者（n=60）相比，中位总生存期（OS；41.0 个月与 OS 未达到，P=0.009）和无进展生存期（28.0 个月与 73.0 个月，P=0.031）更差。这种关联主要是由于接受放化疗的患者（高 XRCC1 表达和低 XRCC1 表达患者的中位 OS 分别为 35.5 个月和未达到，HR 3.48；95%CI：1.44-8.38；P=0.006）。在未接受放化疗的患者中，XRCC1 表达与生存无差异。在多变量分析中，高 XRCC1 表达和 p16（INK4a）阳性状态在整个研究人群中与生存相关（HR=2.62；95%CI：1.52-4.52；P<0.001 和 HR=0.21；95%CI：0.06-0.71；P=0.012），在接受放化疗的患者中也是如此（HR=6.02；95%CI：2.36-15.37；P<0.001 和 HR=0.26；95%CI：0.08-0.92；P=0.037）。
在 HNSCC 中，高 XRCC1 蛋白表达与生存不良相关，特别是在接受放化疗的患者中。这些发现的进一步验证可能使识别受益于放化疗治疗的 HNSCC 表达患者成为可能。
